Oppenheimer analyst Jay Olson lowered the firm’s price target on Biogen to $310 from $320 and keeps an Outperform rating on the shares. The firm notes Biogen provided Q4 financial results and focused on a business update suggesting uncertainty in multiple areas, including 2023 financial guidance with revenues described in rough percentage terms; plans for two potentially transformative product launches with limited insights on timeline to revenue accretion; cost management and R&D prioritization plans with unspecified goals; strategic plans for sustained growth but no Head of Research or Bus Dev to execute; organizational uncertainty surrounding the two aforementioned slots plus the Chairman transition; and apparent consideration for diversifying away from neuroscience. However, Oppenheimer remains optimistic about zuranolone and Leqembi.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72
- Biogen reports Q4 EPS $4.05, consensus $3.48
- Notable companies reporting before tomorrow’s open
- Hyperfine could have ‘interesting’ opportunity in Alzheimer’s, says Evercore ISI
- Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
